{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:16:11Z","timestamp":1792548971647,"version":"4.5.0"},"reference-count":74,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n In 2016, the Centers for Disease Control and Prevention (CDC) published guidelines cautioning against prescribing opioids for chronic noncancer pain. Little is known about unintended outcomes of this guideline on analgesic prescribing for older adults with cancer, who commonly require opioids as first-line pain treatment.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine whether the 2016 CDC guideline was associated with altered analgesic prescribing among older adults with cancer.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n Interrupted time series analysis of a longitudinal cohort using Medicare Current Beneficiary Survey (MCBS) dataset (2010-2020), a nationally representative longitudinal survey of Medicare beneficiaries linked to Medicare claims. MCBS participants older than 65 years who reported a non\u2013skin cancer diagnosis were followed up for up to 4 years. Subgroup analysis conducted for those with poor prognosis cancer or a cancer-related pain encounter (advanced cancer\/cancer pain). Data were analyzed from January 2023 to February 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n CDC Guideline for Prescribing Opioids for Chronic Pain publication in March 2016.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Quarterly prescribing rates of opioids (typical opioids, tramadol, and buprenorphine) and gabapentinoids (gabapentin and pregabalin). For each time series analysis outcome, a level change estimated immediate change and trend (ie, slope) change estimated ongoing change following the guideline.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The cohort included 11\u202f903 older adults with cancer (mean [IQR] age, 79.4 [73-85] years, 6504 [54.6%] women), including 1283 with advanced cancer or cancer pain. Compared with preguideline trends, we observed the following changes after the guideline release: the slope of opioid prescribing decreased (typical opioids: \u22120.47; 95% CI, \u22120.63 to \u22120.30 percentage points [pp]\/quarter; tramadol: \u22120.27; 95% CI, \u22120.36 to \u22120.17 pp\/quarter; buprenorphine: \u22120.01; 95% CI, \u22120.02 to \u22120.01 pp\/quarter), though tramadol prescribing rose by 11.5% overall; and gabapentinoid prescribing increased by 24.9% (slope change, \u22120.03; 95% CI, \u22120.09 to 0.02 pp\/quarter).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study of older adults with cancer, the 2016 CDC guideline was associated with a decline in opioid prescribing that was less pronounced for tramadol compared with typical opioids and was followed by a 25% increase in gabapentinoid prescribing. This may reflect a shift in cancer pain management from first-line opioids to tramadol, which is less safe, and gabapentinoids, which have been shown to be less effective for cancer pain treatment.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.9043","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T11:48:13Z","timestamp":1746618493000},"page":"e259043","source":"Crossref","is-referenced-by-count":15,"title":["The 2016 CDC Opioid Guideline and Analgesic Prescribing Patterns in Older Adults With Cancer"],"prefix":"10.1001","volume":"8","author":[{"given":"Rebecca","family":"Rodin","sequence":"first","affiliation":[{"name":"Brookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Li","sequence":"additional","affiliation":[{"name":"Brookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"McKendrick","sequence":"additional","affiliation":[{"name":"Brookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Harrison","sequence":"additional","affiliation":[{"name":"Division of Geriatrics, Department of Medicine, University of California, San Francisco"},{"name":"Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren J.","family":"Hunt","sequence":"additional","affiliation":[{"name":"Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco"},{"name":"Department of Epidemiology & Biostatistics, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Muench","sequence":"additional","affiliation":[{"name":"Department of Epidemiology & Biostatistics, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cardinale B.","family":"Smith","sequence":"additional","affiliation":[{"name":"Brookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Division of Hematology and Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa D.","family":"Aldridge","sequence":"additional","affiliation":[{"name":"Brookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Sean","family":"Morrison","sequence":"additional","affiliation":[{"name":"Brookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"J.J. Peters VA Medical Center, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"issue":"24","key":"zoi250329r2","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1056\/NEJMp1904190","article-title":"No shortcuts to safer opioid prescribing.","volume":"380","author":"Dowell","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi250329r3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.11826","article-title":"Association of the 2016 US Centers for Disease Control and Prevention opioid prescribing guideline with changes in opioid dispensing after surgery.","volume":"4","author":"Sutherland","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"5","key":"zoi250329r4","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1001\/jamainternmed.2023.8538","article-title":"Opioid prescribing and outcomes in patients with sickle cell disease post-2016 CDC guideline.","volume":"184","author":"Kang","year":"2024","journal-title":"JAMA Intern Med"},{"key":"zoi250329r5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01413","author":"Enzinger","year":"2023","journal-title":"J Clin Oncol"},{"issue":"26","key":"zoi250329r6","doi-asserted-by":"publisher","first-page":"2948","DOI":"10.1200\/JCO.21.00476","article-title":"US trends in opioid access among patients with poor prognosis cancer near the end-of-life.","volume":"39","author":"Enzinger","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi250329r7","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1093\/jnci\/djaa110","article-title":"Temporal trends in opioid prescribing patterns among oncologists in the Medicare population.","volume":"113","author":"Jairam","year":"2021","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"zoi250329r8","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1001\/jama.2021.10161","article-title":"Prescription drug monitoring program mandates and opioids dispensed following emergency department encounters for patients with sickle cell disease or cancer with bone metastasis.","volume":"326","author":"Zhang","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"zoi250329r9","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/jnci\/djac017","article-title":"Impacts of an opioid safety initiative on US veterans undergoing cancer treatment.","volume":"114","author":"Vitzthum","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"zoi250329r10","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkad006","article-title":"The effect of cancer exemption in mandatory-access prescription drug monitoring programs among oncologists.","volume":"7","author":"Graetz","year":"2023","journal-title":"J Natl Cancer Inst Cancer Spectr"},{"issue":"1","key":"zoi250329r11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024.","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"zoi250329r12","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/cancers15030591","article-title":"Update on prevalence of pain in patients with cancer 2022: a systematic literature review and meta-analysis.","volume":"15","author":"Snijders","year":"2023","journal-title":"Cancers (Basel)"},{"key":"zoi250329r13","doi-asserted-by":"publisher","author":"Paice","journal-title":"J Clin Oncol","DOI":"10.1200\/JCO.22.02198"},{"key":"zoi250329r15","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1200\/EDBK_180469","article-title":"Pain and opioids in cancer care: benefits, risks, and alternatives.","volume":"37","author":"Bennett","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"7","key":"zoi250329r16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012592","article-title":"Opioids for cancer pain\u2014an overview of Cochrane reviews.","volume":"7","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"26","key":"zoi250329r17","doi-asserted-by":"publisher","first-page":"E786","DOI":"10.1503\/cmaj.171333","article-title":"Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis.","volume":"190","author":"Enke","year":"2018","journal-title":"CMAJ"},{"issue":"8","key":"zoi250329r18","doi-asserted-by":"publisher","first-page":"977","DOI":"10.6004\/jnccn.2019.0038","article-title":"Adult cancer pain, version 3.2019, NCCN clinical practice guidelines in oncology.","volume":"17","author":"Swarm","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"zoi250329r19","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1001\/jamainternmed.2022.3680","article-title":"Perioperative gabapentin use and in-hospital adverse clinical events among older adults after major surgery.","volume":"182","author":"Park","year":"2022","journal-title":"JAMA Intern Med"},{"issue":"3","key":"zoi250329r20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193134","article-title":"Gabapentin dose and the 30-day risk of altered mental status in older adults: A retrospective population-based study.","volume":"13","author":"Fleet","year":"2018","journal-title":"PLoS One"},{"issue":"9","key":"zoi250329r21","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1111\/acer.14408","article-title":"Safety of gabapentin prescribed for any indication in a large clinical cohort of 571,718 US veterans with and without alcohol use disorder.","volume":"44","author":"Rentsch","year":"2020","journal-title":"Alcohol Clin Exp Res"},{"issue":"4","key":"zoi250329r25","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1093\/pm\/pny307","article-title":"Challenges with implementing the centers for disease control and prevention opioid guideline: a consensus panel report.","volume":"20","author":"Kroenke","year":"2019","journal-title":"Pain Med"},{"issue":"8","key":"zoi250329r26","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi250329r27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1158\/1055-9965.EPI-21-0835","article-title":"Validation of self-reported cancer diagnoses using medicare diagnostic claims in the US health and retirement study, 2000-2016.","volume":"31","author":"Mullins","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"zoi250329r28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jamainternmed.2014.5260","article-title":"Tramadol and hypoglycemia: one more thing to worry about.","volume":"175","author":"Nelson","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"8","key":"zoi250329r29","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.121592","article-title":"Tramadol.","volume":"185","author":"Young","year":"2013","journal-title":"CMAJ"},{"key":"zoi250329r30","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2007.06.011","author":"Le Berre","year":"2007","journal-title":"Rev Med Interne"},{"issue":"127","key":"zoi250329r32","first-page":"37623","article-title":"Schedule of controlled substances: placement of tramadol into schedule IV. Final rule.","volume":"79","author":"Drug Enforcement Administration, Department of Justice","year":"2014","journal-title":"Fed Regist"},{"issue":"1","key":"zoi250329r34","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00520-019-05100-9","article-title":"Use of gabapentinoid medications among US adults with cancer, 2005-2015.","volume":"28","author":"Fauer","year":"2020","journal-title":"Support Care Cancer"},{"issue":"5","key":"zoi250329r35","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMp1704633","article-title":"Gabapentin and pregabalin for pain\u2014is increased prescribing a cause for concern?","volume":"377","author":"Goodman","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi250329r36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC clinical practice guideline for prescribing opioids for pain\u2014United States, 2022.","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR Recomm Rep"},{"issue":"9","key":"zoi250329r37","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.32979","article-title":"Mortality and function after widowhood among older adults with dementia, cancer, or organ failure.","volume":"7","author":"Rodin","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zoi250329r38","doi-asserted-by":"publisher","first-page":"367","DOI":"10.7326\/M18-1243","article-title":"Opioid prescribing in the United States before and after the Centers for Disease Control and Prevention\u2019s 2016 opioid guideline.","volume":"169","author":"Bohnert","year":"2018","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi250329r39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6501e1","article-title":"CDC Guideline for prescribing opioids for chronic pain\u2014United States, 2016.","volume":"65","author":"Dowell","year":"2016","journal-title":"MMWR Recomm Rep"},{"issue":"5","key":"zoi250329r40","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014682.pub2","article-title":"Antidepressants for pain management in adults with chronic pain: a network meta-analysis.","volume":"5","author":"Birkinshaw","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"zoi250329r42","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.2147\/JPR.S285835","article-title":"The United States drug enforcement administration and prescription opioid production quotas: an end game of eradication?","volume":"13","author":"Schatman","year":"2020","journal-title":"J Pain Res"},{"issue":"1","key":"zoi250329r47","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.4316","article-title":"A national opioid tax for treatment programs in the US: funding opportunity but problems ahead.","volume":"3","author":"Harris","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"21","key":"zoi250329r50","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1001\/jama.2019.5188","article-title":"Limits on opioid prescribing leave patients with chronic pain vulnerable.","volume":"321","author":"Rubin","year":"2019","journal-title":"JAMA"},{"issue":"2","key":"zoi250329r51","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11096-020-01129-7","article-title":"Unintended consequences of United States chronic pain guidelines.","volume":"43","author":"Adams","year":"2021","journal-title":"Int J Clin Pharm"},{"issue":"7","key":"zoi250329r52","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.jpain.2022.01.006","article-title":"Trends in prescriptions for non-opioid pain medications among U.S. adults with moderate or severe pain, 2014-2018.","volume":"23","author":"Gorfinkel","year":"2022","journal-title":"J Pain"},{"issue":"3","key":"zoi250329r53","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00520-014-2415-9","article-title":"Use of non-opioid analgesics as adjuvants to opioid analgesia for cancer pain management in an inpatient palliative unit: does this improve pain control and reduce opioid requirements?","volume":"23","author":"Shinde","year":"2015","journal-title":"Support Care Cancer"},{"issue":"1","key":"zoi250329r54","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1177\/0269216317711826","article-title":"Opioids combined with antidepressants or antiepileptic drugs for cancer pain: systematic review and meta-analysis.","volume":"32","author":"Kane","year":"2018","journal-title":"Palliat Med"},{"issue":"3","key":"zoi250329r55","doi-asserted-by":"publisher","first-page":"174","DOI":"10.2174\/157488710792007310","article-title":"Gabapentin for the treatment of cancer-related pain syndromes.","volume":"5","author":"Bar Ad","year":"2010","journal-title":"Rev Recent Clin Trials"},{"issue":"2","key":"zoi250329r56","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jpainsymman.2006.11.013","article-title":"Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial.","volume":"34","author":"Keskinbora","year":"2007","journal-title":"J Pain Symptom Manage"},{"issue":"14","key":"zoi250329r57","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1200\/JCO.2004.08.141","article-title":"Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group.","volume":"22","author":"Caraceni","year":"2004","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi250329r58","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/annonc\/mdw097","article-title":"Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV \u2018real life\u2019 trial on the variability of response to opioids.","volume":"27","author":"Corli","year":"2016","journal-title":"Ann Oncol"},{"key":"zoi250329r61","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0028","author":"Tevaarwerk","year":"2021","journal-title":"J Nat Comp Cancer Netw"},{"issue":"27","key":"zoi250329r62","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.2016.68.5206","article-title":"Management of chronic pain in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline.","volume":"34","author":"Paice","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi250329r64","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/ije\/dyw098","article-title":"Interrupted time series regression for the evaluation of public health interventions: a tutorial.","volume":"46","author":"Bernal","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"12","key":"zoi250329r65","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1111\/add.16324","article-title":"Changes to opioid overdose deaths and community naloxone access among Black, Hispanic and White people from 2016 to 2021 with the onset of the COVID-19 pandemic: an interrupted time-series analysis in Massachusetts, USA.","volume":"118","author":"Zang","year":"2023","journal-title":"Addiction"},{"issue":"9","key":"zoi250329r66","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s40264-022-01209-9","article-title":"Impact of policy interventions on oxycodone prescribing in Queensland, Australia: an uncontrolled interrupted time series study.","volume":"45","author":"Tumusiime","year":"2022","journal-title":"Drug Saf"},{"issue":"12","key":"zoi250329r67","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1001\/jamasurg.2018.2651","article-title":"Association of hydrocodone schedule change with opioid prescriptions following surgery.","volume":"153","author":"Habbouche","year":"2018","journal-title":"JAMA Surg"},{"issue":"3","key":"zoi250329r68","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1001\/jama.2019.18913","article-title":"Trends in buprenorphine treatment in the United States, 2009-2018.","volume":"323","author":"Olfson","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"zoi250329r70","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/papr.12459","article-title":"Pharmacological treatment of pain in cancer patients: the role of adjuvant analgesics, a systematic review.","volume":"17","author":"van den Beuken-van Everdingen","year":"2017","journal-title":"Pain Pract"},{"issue":"9","key":"zoi250329r71","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00228-006-0161-8","article-title":"Use of tricyclic antidepressants in older patients with painful neuropathies.","volume":"62","author":"Berger","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"zoi250329r72","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jpainsymman.2023.05.002","article-title":"Is acetaminophen beneficial in patients with cancer pain who are on strong opioids? A randomized controlled trial.","volume":"66","author":"Leiva-V\u00e1squez","year":"2023","journal-title":"J Pain Symptom Manage"},{"issue":"7","key":"zoi250329r73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012637.pub2","article-title":"Oral paracetamol (acetaminophen) for cancer pain.","volume":"7","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"zoi250329r74","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1016\/j.bja.2019.02.028","article-title":"Nonsteroidal anti-inflammatory drugs and pain in cancer patients: a systematic review and reappraisal of the evidence.","volume":"123","author":"Magee","year":"2019","journal-title":"Br J Anaesth"},{"key":"zoi250329r48","volume-title":"Dopesick: dealers, doctors, and the drug company that addicted America","author":"Macy","year":"2018"},{"key":"zoi250329r49","volume-title":"Empire of Pain: The Secret History of the Sackler Dynasty","author":"Keefe","year":"2021"},{"key":"zoi250329r60","volume-title":"Therapeutics Letter. Therapeutics Initiative 1994\u20142022 Therapeutics Initiative","author":"Perry","year":"1994"},{"key":"zoi250329r63","volume-title":"Clinical Practice Guidelines for Quality Palliative Care","year":"2018"},{"key":"zoi250329r69","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1017\/CBO9780511544835.021","volume-title":"Emergency Department Analgesia: An Evidence-Based Guide. Cambridge University Press","author":"Walta","year":"2008"},{"key":"zoi250329r1","unstructured":"Centers for Disease Control and Prevention. Drug overdose deaths. Accessed January 9, 2024. https:\/\/www.cdc.gov\/drugoverdose\/deaths\/index.html"},{"key":"zoi250329r14","unstructured":"ASCO. ASCO policy statement on opioid therapy: Protecting access to treatment for cancer-related pain. Accessed May 11, 2022. https:\/\/www.asco.org\/sites\/new-www.asco.org\/files\/content-files\/advocacy-and-policy\/documents\/2016-ASCO-Policy-Statement-Opioid-Therapy.pdf"},{"key":"zoi250329r22","unstructured":"Dowell D. CDC opioid guideline clarification letter to ASCO, ASH, NCCN. Accessed June 1, 2023. https:\/\/old-prod.asco.org\/sites\/new-www.asco.org\/files\/content-files\/advocacy-and-policy\/documents\/2019-CDC-Opioid-Guideline-Clarification-Letter-to-ASCO-ASH-NCCN.pdf"},{"key":"zoi250329r23","unstructured":"Brennan TA, Creager R, Polinski JM. Pharmacy benefit management of opioid prescribing: the role of employers and insurers. Health Affairs. September 21, 2017. Accessed February 1, 2024. https:\/\/www.healthaffairs.org\/content\/forefront\/pharmacy-benefit-management-opioid-prescribing-role-employers-and-insurers"},{"key":"zoi250329r24","unstructured":"New data: some measures meant to address opioid abuse are having adverse impact on access to legitimate pain care for patients. American Cancer Society. June 14, 2018. Accessed August 26, 2024. https:\/\/www.fightcancer.org\/releases\/new-data-some-measures-meant-address-opioid-abuse-are-having-adverse-impact-access"},{"key":"zoi250329r31","unstructured":"The Associated Press. How tramadol, touted as safer opioid, became 3rd world peril. U.S. News & World Report. Updated December 13, 2019. Accessed October 18, 2024. https:\/\/www.usnews.com\/news\/business\/articles\/2019-12-13\/another-opioid-crisis-is-raging-through-the-developing-world"},{"key":"zoi250329r33","doi-asserted-by":"crossref","unstructured":"Arthur? J, Edwards? T, Lu? Z, . Healthcare provider perceptions and reported practices regarding opioid prescription for patients with chronic pain.? Res Sq. Preprint posted online September 27, 2023. doi:10.21203\/rs.3.rs-3367358\/v1","DOI":"10.1007\/s00520-024-08323-7"},{"key":"zoi250329r41","unstructured":"National Opioids Settlement. Accessed April 1, 2024. https:\/\/nationalopioidsettlement.com\/"},{"key":"zoi250329r43","unstructured":"DEA. DEA Proposes to reduce the amount of five opioids manufactured in 2020, marijuana quota for research increases by almost a third. United States Drug Enforcement Administration. Accessed April 1, 2024. https:\/\/www.dea.gov\/press-releases\/2019\/09\/11\/dea-proposes-reduce-amount-five-opioids-manufactured-2020-marijuana-quota"},{"key":"zoi250329r44","unstructured":"DEA reduces amount of opioid controlled substances to be manufactured in 2017. United States Drug Enforcement Agency. October 6, 2016. Accessed July 22, 2024. https:\/\/www.dea.gov\/press-releases\/2016\/10\/04\/dea-reduces-amount-opioid-controlled-substances-be-manufactured-2017"},{"key":"zoi250329r45","unstructured":"Established aggregate production quotas for Schedule I and II controlled substances and assessment of annual needs for the List I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine for 2023. United States Drug Enforcement Agency. December 2, 2022. Accessed July 22, 2024. https:\/\/www.govinfo.gov\/content\/pkg\/FR-2022-12-02\/pdf\/2022-26351.pdf"},{"key":"zoi250329r46","unstructured":"Brian Mann? AP. Carrie Feibel. Supreme Court overturns opioid settlement with Purdue Pharma that shielded Sacklers. NPR. Accessed July 29, 2024. https:\/\/www.npr.org\/sections\/shots-health-news\/2024\/06\/29\/nx-s1-5021798\/supreme-court-overturns-opioid-settlement-with-purdue-pharma-that-shielded-sacklerssupreme-court-overturns-sackler-settlement-delaying-funds-meant-for-communities-battling-opioids"},{"key":"zoi250329r59","unstructured":"Drug Enforcement Administration. Controlled substance schedules. Accessed October 18, 2024. https:\/\/www.deadiversion.usdoj.gov\/schedules\/schedules.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2833616\/rodin_2025_oi_250329_1745961515.77807.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T11:48:26Z","timestamp":1746618506000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2833616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":74,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.9043","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]}}}